Investor Presentaiton
Cardiovascular
milvexian
Camzyos
Emerging data suggests a potential role for MYK-224 in
HFPEF
MYK-224
MYK-224 profile as a cardiac myosin inhibitor
Pre-clinical animal models show similar
exposure-response with mavacamten¹
MYK-224 OHCM Phase 2 MERCUTIO trial is ongoing
to confirm exposure-response similarity in
humans
Role of cardiac myosin inhibitor in HFPEF
Encouraging interim observations from
mavacamten Phase 2a EMBARK suggests myosin
inhibitor benefits in HFPEF
Leveraging entirety of cardiac myosin inhibitor
data and experience to support starting dose for
MYK-224 in HFPEF
Initiate MYK-224 PoC in HFpEF in 2023/2024
Ill Bristol Myers Squibb™
1. Preclinical model only tested in 'prevention', not 'treatment' mode
Not for Product Promotional Use
124View entire presentation